Dalila A.
- Country
- France
- Department
- Paediatric haematology oncology
Research Overview
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Phase II Randomized Study of Bortezomib with Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase, and Methotrexate in High-Risk Relapsed Pediatric ALL
- Phase III Randomized Trial of Gemtuzumab Ozogamicin with Induction Chemotherapy in Pediatric Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Myeloid Sarcoma
Data & Insights
Has run more than one trial at 128 of 199 partner sites.
Specializations
Acute Lymphoblastic Leukemia
The investigator specializes in treating acute lymphoblastic leukemia, with particular expertise in managing Philadelphia chromosome-positive ALL in pediatric patients. Their research encompasses both standard-risk and high-risk disease classifications.
- Standard Risk ALL Management
- Philadelphia Chromosome-Positive ALL
- Relapsed ALL Treatment
Their work extends to investigating novel therapeutic combinations and treatment optimization strategies.
Acute Myeloid Conditions
The investigator focuses on acute myeloid leukemia and related conditions, including high-risk myelodysplastic syndrome and isolated myeloid sarcoma.
- Newly Diagnosed AML Treatment
- Advanced MDS Management
- Stem Cell Transplantation Approaches
Their expertise includes both conventional and innovative therapeutic strategies for myeloid malignancies.
Treatment Resistance
The investigator addresses treatment-resistant leukemia, with particular attention to high-risk relapsed cases requiring advanced therapeutic interventions.
- High-Risk Relapse Management
- Novel Drug Combinations
- Resistance Pattern Analysis
Their work involves evaluating innovative therapeutic approaches for resistant disease states.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.